Unjha Formulations Ltd

Unjha Formulations Ltd

$UNJHAFORPharmaceuticalsBSE

Unjha Formulations Ltd (UNJHAFOR) last traded at ₹25.1, a market capitalisation of ₹11.2 crore, on a P/E of 23.4. Over the past 52 weeks the stock has ranged between ₹17.5 and ₹29.5. Unjha Formulations Ltd last reported results for the quarter ended Jun 2026, with sales of ₹3.31 crore and net profit of ₹0.16 crore. Figures are as of 25 Aug 2026 and are not real time.

Unjha Formulations Ltd share price and key metrics

Current price
₹25.1
Market cap
₹11.2 cr
Stock P/E
23.4
Book value
₹8.57
ROE
20.1%
ROCE
27.8%
Dividend yield
0.00%
52w high / low
29.5/17.5

Metrics as of 25 Aug 2026. Not real time.

Unjha Formulations Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹3.31 cr, down 8.8% from ₹3.63 cr a year earlier. Net profit was ₹0.16 cr, down 59.0% year on year.

Unjha Formulations Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales3.783.762.443.634.294.443.333.31
Expenses3.893.522.73.213.54.163.783.12
Operating profit-0.110.24-0.260.420.790.28-0.450.19
OPM %-2.91%6.38%-10.66%11.57%18.41%6.31%-13.51%5.74%
Other income0.020.01000.06000
Interest00000000
Depreciation0.020.020.030.030.030.040.040.04
Profit before tax-0.110.23-0.290.390.820.24-0.490.15
Tax %0.00%0.00%41.38%0.00%0.00%0.00%51.02%0.00%
Net profit-0.110.22-0.410.390.820.24-0.740.16
EPS (₹)-0.250.49-0.920.871.830.54-1.650.36

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Unjha Formulations Ltd annual results

Unjha Formulations Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales9.9614.1613.1518.513.8615.5915.37
Operating profit0.130.320.440.570.520.950.81
OPM %1.31%2.26%3.35%3.08%3.75%6.09%5.27%
Net profit0.10.250.280.280.410.70.48
EPS (₹)0.220.560.620.620.921.561.08

TTM is the trailing twelve months to the most recent quarter.

Unjha Formulations Ltd growth and returns

Compounded Sales Growth
10 Years
4%
5 Years
9%
3 Years
6%
TTM
13%
Compounded Profit Growth
10 Years
10%
5 Years
48%
3 Years
36%
TTM
433%
Stock Price CAGR
10 Years
10%
5 Years
21%
3 Years
23%
1 Year
0%
Return on Equity
10 Years
16%
5 Years
14%
3 Years
15%
Last Year
20%

Unjha Formulations Ltd shareholding pattern

Promoters held 36.92% at Jun 2026, broadly unchanged since Jun 2025.

Unjha Formulations Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters36.92%36.92%36.92%36.92%36.92%36.92%36.92%36.92%
Public63.07%63.07%63.07%63.08%63.08%63.08%63.08%63.07%
No. of shareholders3,9694,2084,2734,2134,2844,2514,2354,223

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Unjha Formulations Ltd corporate filings

  • REGULATION 44(3) OF SEBI(LODR) REGULATION ,2015 / SCRUTINIZER REPORTAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Unjha Formulations Limited has disclosed the voting results for its 32nd Annual General…

    Read the full analysis
  • Filing Of Distribution ScheduleCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Unjha Formulations Ltd has submitted its distribution schedule in compliance with SEBI…

    Read the full analysis
  • Cash Flow Statement for the year ended 31.03.2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Unjha Formulations Ltd has filed its Cash Flow Statement for the financial year ended…

    Read the full analysis
  • Cash Flow Statement for the year ended 31.03.2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Unjha Formulations Ltd has filed its Cash Flow Statement for the financial year ended…

    Read the full analysis
  • REGULATION 30 OF THE SEBI (LODR) 2015, OUTCOME OF AGM HELD ON 14-08-2026AGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Unjha Formulations Limited has successfully concluded its 32nd Annual General Meeting…

    Read the full analysis
  • REG 33 (3) OF SEBI (LODR) ACT 2015Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Unjha Formulations Limited reported a decline in performance for the quarter ended 30…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Unjha Formulations Ltd

Cruxal reads every Unjha Formulations Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Unjha Formulations Ltd (UNJHAFOR) Results, Financials & Share Price | Cruxal